Skip to main content
. 2019 Feb 4;2019:4905013. doi: 10.1155/2019/4905013

Table 6.

Incidence of AEs in ≥5% of patients by treatment.

AE, n (%) Fentanyl matrix (N = 52) Gabapentin (N = 56) Total (N = 108)
Dizziness 16 (30.8%) 25 (44.6%) 41 (38.0%)
Somnolence 15 (28.8%) 21 (37.5%) 36 (33.3%)
Nausea 19 (36.5%) 4 (7.1%) 23 (21.3%)
Constipation 8 (15.4%) 10 (17.9%) 18 (16.7%)
Vomiting 11 (21.2%) 2 (3.6%) 13 (12.0%)
Asthenia 7 (13.5%) 8 (14.3%) 15 (13.9%)
Headache 3 (5.8%) 4 (7.1%) 7 (6.5%)

AE: adverse event.